Premium
Maternal and neonatal outcomes in 80 patients diagnosed with non‐Hodgkin lymphoma during pregnancy: results from the International Network of Cancer, Infertility and Pregnancy
Author(s) -
Maggen Charlotte,
Dierickx Daan,
Cardonick Elyce,
Mhallem Gziri Mina,
CabreraGarcia Alvaro,
Shmakov Roman G.,
Avivi Irit,
Masturzo Bianca,
Duvekot Johannes J.,
Ottevanger Petronella B.,
O’Laughlin Andie,
Polushkina Evgeniya,
Van Calsteren Kristel,
WoeiAJin F.J. Sherida H.,
Amant Frédéric
Publication year - 2021
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.17103
Subject(s) - medicine , pregnancy , obstetrics , vincristine , rituximab , lymphoma , pediatrics , cyclophosphamide , chemotherapy , genetics , biology
Summary This cohort study of the International Network on Cancer, Infertility and Pregnancy (INCIP) reports the maternal and neonatal outcomes of 80 pregnant patients diagnosed with non‐Hodgkin lymphoma (NHL) between 1986 and 2019, focussing on 57 (71%) patients with diffuse large B‐cell lymphoma (DLBCL). Of all 80 patients, 54 (68%) pregnant patients received chemotherapy; mostly (89%) CHOP‐like (cyclophosphamide, doxorubicin, vincristine, and prednisone) regimens. Four early pregnancies were terminated. Among 76 ongoing pregnancies, there was one stillbirth (1·3%). Overall, there was a high incidence of small for gestational age neonates (39%), preterm delivery (52%), obstetric (41%) and neonatal complications (12·5%), and this could not exclusively be explained by the receipt of antenatal chemotherapy. Half of preterm deliveries (46%) were planned in order to tailor oncological treatment. The 3‐year progression‐free and overall survival for patients with DLBCL treated with rituximab‐CHOP was 83·4% and 95·7% for limited stage ( n = 29) and 60·6% and 73·3% for advanced stage ( n = 15). Of 36 pregnant patients who received rituximab, five (13%) cases with neonatal complications and three (8%) with maternal infections were reported. In conclusion, standard treatment for DLBCL can be offered to pregnant patients in obstetric centres that cater for high‐risk patients.